X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acetylcholine Receptor | Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology (MSH). | ILX:0100242 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acetylcholine-gated channel (nicotinic) | This is an acetylcholine binding, cationic channel, which is primarily found on the muscle tissue of vertebrates. | ILX:0100243 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acetylcholinesterase | An enzyme that catalyzes the hydrolysis of acetylcholine to choline and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. (MSH) | ILX:0100244 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acetyldigitoxin | Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure. Pharmacology: The main pharmacological effects of acetyldigitoxin are on the heart. Extracardiac effects are responsible for many of the adverse effects. Its main cardiac effects are 1) a decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter, and 2) an increase of force of contraction via inhibition of the Na+/K+ ATPase pump. Mechanism of action: Acetyldigitoxin binds to a site on the extracellular aspect of the -subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by acetyldigitoxin. This is a different mechanism from that of catecholamines. Acetyldigitoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias. Drug type: Approved. Small Molecule. Drug category: Anti-Arrhythmia Agents. Cardiotonic Agents. Enzyme Inhibitors | ILX:0100245 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Aciclovir | A guanosine analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. (PubChem) Pharmacology: Aciclovir (INN) or acyclovir (USAN, former BAN) is a synthetic deoxyguanosine analog and it is the prototype antiviral agent that is activated by viral thymidine kinase. The selective activity of aciclovir is due to its affinity for the thymidine kinase enzyme encoded by HSV and VZV. Mechanism of action: Viral (HSV-1, HSV-2 and VZV) thymidine kinase converts aciclovir to the aciclovir monophosphate, which is then converted to the diphosphate by cellular guanylate kinase, and finally to the triphosphate by phosphoglycerate kinase, phosphoenolpyruvate carboxykinase, and pyruvate kinase. Aciclovir triphosphate competitively inhibits viral DNA polymerase and competes with the natural deoxyguanosine triphosphate, for incorporation into viral DNA. Once incorporated, aciclovir triphosphate inhibits DNA synthesis by acting as a chain terminator. Drug type: Approved. Small Molecule. Drug category: Antiviral Agents. Nucleosides and Nucleotides | ILX:0100246 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acidic | An acidity inhering in a solution by virtue of its high concentration of H+ ions. | ILX:0100247 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acidity | A quality inhering in an entity by virtue of containing acid (hydrogen ions). | ILX:0100248 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acitretin | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. (PubChem) Pharmacology: Acitretin is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling. Mechanism of action: The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors) in the skin which help normalize the growth cycle of skin cells. Drug type: Approved. Small Molecule. Drug category: Keratolytic Agents | ILX:0100249 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acknowledgement requested | No license has been specified but owner has requested acknowledgement, usually with specific instructions. | ILX:0100250 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acknowledgement required | No license has been specified but owner has required attribution, usually with specific instructions on how to do so. | ILX:0100251 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acoelomata | ILX:0100252 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Acoustic startle response test | Test of the acoustic startle reflex response, an exaggerated flinching response to unexpected auditory stimuli. | ILX:0100253 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition | the planned process of gaining possession of a continuant | ILX:0100254 | 4 | scicrunch | 06/12/2021 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition Contrast | Indication of acquisition contrast used with frames in the SOP Instance. | ILX:0100255 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition Date | The date the acquisition of data that resulted in this image started | ILX:0100256 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Acquisition Datetime | The date and time that the acquisition of data that resulted in this image started. Note: The synchronization of this time with an external clock is specified in the Synchronization Module in Acquisition Time Synchronized (0018,1800). | ILX:0100257 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition Device Type Code Sequence | Describes the type of acquisition device. Only a single Item shall be included in this Sequence. | ILX:0100258 | 5 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Acquisition Duration | The time in seconds needed to run the prescribed pulse sequence. Required if Image Type (0008,0008) Value 1 is ORIGINAL or MIXED. May be present otherwise. | ILX:0100259 | 5 | scicrunch | 06/16/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition Matrix | Dimensions of the acquired frequency /phase data before reconstruction. Multi-valued: frequency rowsfrequency columnsphase rowsphase columns. | ILX:0100260 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Acquisition Number | A number identifying the single continuous gathering of data over a period of time that resulted in this image or instance, which may include multiple bed positions. This number is not required to be unique across SOP Instances in a series. | ILX:0100261 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X